First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients
Cited by 129
Related Papers
Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature
|Molecular Pharmaceutics|2018|91
68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1/2 clinical trial
|Nature Communications|2024|23
CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
|Cancer Discovery|2024|23
Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: A prospective single-arm comparative clinical trial.
|Journal of Clinical Oncology|2024|1